Target intelligence / Profile preview

Smooth muscle myosin (Myosin-11) (MYH11)

Target
MYH11
Molecular classification
Enzyme, Motor protein, Myosin
01

Overview

The Ca2+-dependent myofibrillar ATPase in vascular smooth muscle refers to the enzymatic activity of the smooth muscle myosin complex (primarily Myosin-11), which serves as the molecular motor for vascular contraction (NIH, 2023). Unlike striated muscle, where calcium regulation is mediated by the troponin complex, smooth muscle contraction is primarily controlled by the calcium-calmodulin-dependent activation of Myosin Light Chain Kinase (MLCK) (ResearchGate, 2022). MLCK phosphorylates the 20 kDa regulatory light chain (MLC20), which triggers the myofibrillar ATPase activity and initiates cross-bridge cycling (ResearchGate, 2022). This ATPase activity is essential for maintaining vascular tone and regulating blood pressure, and its dysregulation is a key factor in the pathogenesis of hypertension, vasospasm, and atherosclerosis (Annual Reviews, 1987). Mutations in the MYH11 gene, which encodes the smooth muscle myosin heavy chain, are specifically associated with hereditary thoracic aortic aneurysms and dissections (UniProt, 2024). Pharmacological modulation of this system includes the use of calmodulin antagonists and MLCK inhibitors, which directly reduce the calcium-dependent activation of the myofibrillar ATPase (PubMed, 1980). Additionally, certain clinical agents like bepridil and perhexiline have been shown to inhibit this contractile engine, offering a direct pathway for vasodilation in cardiovascular therapy (PubMed, 1984). Research into direct myosin inhibitors, such as blebbistatin, continues to provide insights into the potential for more specific therapeutic modulation of vascular contractility (MDPI, 2022).

Other names
Smooth muscle myosin heavy chainSMMHCActomyosin ATPaseMyofibrillar ATPaseVascular smooth muscle myosinCa2+-dependent myofibrillar ATPase
02

Mechanism of action

Inhibition of the myosin ATPase catalytic activity or the calcium-calmodulin-dependent phosphorylation of the myosin light chain required for its activation.

03

Biological functions

Muscle contractionVascular tone regulationATP hydrolysisCross-bridge cycling
04

Disease associations

HypertensionAsthmaThoracic aortic aneurysmVasospasmAtherosclerosis
05

Safety considerations

HypotensionGastrointestinal dysmotilityPotential cross-reactivity with cardiac or skeletal myosin isoforms
06

Interacting drugs

Blebbistatin

8 more in the full profile.

07

Biomarkers

Myosin light chain phosphorylation (p-MLC)MYH11 gene mutationsVascular resistance

Beyond the preview

Go deeper on Smooth muscle myosin (Myosin-11) (MYH11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Smooth muscle myosin (Myosin-11) (MYH11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call